For this purpose, we used a wild-type p53 cell line (MEL202) derived from a primary uveal melanoma, a cancer which rarely has mutated p53 and frequently highly expresses MDMX protein to constrain p53 activity [63]. The gene discussed is MDM4; the disease is uveal melanoma.